Garvey, W. Timothy

Clinical Practice Guidelines For The Perioperative Nutritional, Metabolic, And Nonsurgical Support Of The Bariatric Surgery Patient2013 Update: Cosponsored By American Association Of Clinical Endocrinologists, The Obesity Society, And American Society For Metabolic & Bariatric Surgery

Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Endocrine Practice

Bariatric Surgery and OutcomesEnhanced Recovery After Surgery

Cited by 395

Adiposity-Based Chronic Disease as a new Diagnostic Term: The American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement

Mechanick, J. I., Hurley, D. L., & Garvey, W. T. (2017) · Endocrine Practice

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 320

Limitations in the Use of Indices Using Glucose and Insulin Levels to Predict Insulin Sensitivity

Pisprasert, V., Ingram, K. H., Lopez-Davila, M. F., Munoz, A. J., & Garvey, W. T. (2013) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 302

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 297

Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5

Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 288

Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers

Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and Adiposity

Cited by 243

American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease

Garvey, W. T., Garber, A. J., Mechanick, J. I., Bray, G. A., Dagogo-Jack, S., Einhorn, D., Grunberger, G., Handelsman, Y., Hennekens, C. H., Hurley, D. L., et al. (2014) · Endocrine Practice

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 238

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 238

AACE/ACE comprehensive diabetes management algorithm 2015

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garber, J. R., et al. (2015) · Endocrine Practice

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 225

Critical Evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance With Dyslipidemia

Liao, Y., Kwon, S., Shaughnessy, S., Wallace, P., Hutto, A., Jenkins, A. J., Klein, R. L., & Garvey, W. T. (2004) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Cited by 218

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 215

The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity

Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Obesity

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Function and Risk Factors

Cited by 202

Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system

Hunter, S. J., & Garvey, W. T. (1998) · The American Journal of Medicine

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 200

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 186

Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus.

Garvey, W. T., Huecksteadt, T. P., Matthaei, S., & Olefsky, J. M. (1988) · Journal of Clinical Investigation

Metabolism, Diabetes, and CancerAdipokines, Inflammation, and Metabolic Diseases

Cited by 169

Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study

Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T. (2019) · Diabetes Care

Hormonal and reproductive studiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 164

Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release

Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 149

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 142

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update

Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 141

Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age

Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Metabolic Syndrome and Related Disorders

Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 139

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Kosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 127

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 124

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study

Purnell, J. Q., Braffett, B. H., Zinman, B., Gubitosi-Klug, R. A., Sivitz, W., Bantle, J. P., Ziegler, G., Cleary, P. A., Brunzell, J. D., DCCT/EDIC Research Group, et al. (2017) · Diabetes Care

Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 120